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Introduction: The PARAMOUNT phase III trial demonstrated 
that pemetrexed continuation maintenance significantly reduced the 
risk of disease progression (hazard ratio = 0.62) and death (hazard 
ratio = 0.78) versus placebo in patients with advanced nonsquamous 
non–small-cell lung cancer. To further understand the survival data, 
descriptive subgroup analyses were undertaken.
Methods: Nine hundred thirty-nine patients received induction 
therapy (four 21-day cycles pemetrexed 500 mg/m2 and cisplatin 
75 mg/m2), after which 539 nonprogressing patients with an Eastern 
Cooperative Oncology Group performance status (PS) of 0/1 were 
randomized (2:1) to maintenance pemetrexed (500 mg/m2) cycles or 
placebo until disease progression.
Results: Baseline characteristics of patients surviving for longer 
periods were comparable to patients surviving shorter periods, sug-
gesting overall survival (OS) benefit for all subgroups of patients on 
maintenance therapy. An examination of type and severity of induc-
tion adverse events also found no association with survival duration. 
Response to induction (tumor response versus stable disease) was 
not determinate of pemetrexed maintenance OS outcome as assessed 
by waterfall plot and scattergrams and by the distribution of patients 
among various OS intervals. The length of the interval before begin-
ning maintenance therapy (<7 days versus ≥7/≤30 days) also did not 
impact the survival results. PS, a known prognostic factor, was the 
only baseline characteristic associated with improved OS; however, 
both PS 0 and PS 1 patients exhibited a survival benefit from peme-
trexed maintenance.
Conclusions: In PARAMOUNT, the OS benefit was seen across all 
subgroups. Other than PS, no baseline or clinical parameter clearly 
identified a subgroup more likely to benefit. Maintenance treatment 
decisions should be made on an individual basis.
Key Words: Nonsquamous non–small-cell lung cancer, Pemetrexed, 
Cisplatin, Induction, Maintenance, Phase III, Survival.
(J Thorac Oncol. 2014;9: 205–213)
Platinum-containing first-line chemotherapy has improved overall survival (OS) of patients with advanced non–
small-cell lung cancer (NSCLC), but no additional benefit is 
realized after four to six cycles, and toxicities associated with 
platinum administration often prevent more than this number 
of cycles.1–3 As summarized in a recent review article, results 
of recent phase III trials have demonstrated that once platinum 
is discontinued, nonprogressing patients can derive further 
benefit through administration of maintenance therapy until 
disease progression, patient–physician decision, or unaccept-
able toxicity.4
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Different concepts of maintenance therapy have been 
developed. “Continuation maintenance therapy” continues the 
administration of the nonplatinum component of the chemo-
therapeutic regimen used during the initial, first-line, “induc-
tion” therapy, and “switch maintenance therapy” introduces a 
different nonplatinum compound for maintenance therapy than 
that used for induction. For the treatment of advanced NSCLC, 
erlotinib has yielded a progression-free survival (PFS) and OS 
benefit in a switch maintenance format.5 The strong impact of 
the epidermal growth factor receptor (EGFR) mutation on the 
PFS outcome suggests that switch maintenance with erlotinib 
might be a valid option for patients with an EGFR mutation.6 
Pemetrexed has shown PFS and OS benefit in both the switch 
maintenance and continuation maintenance settings.7–9 The 
accumulation of evidence detailing maintenance therapy effi-
cacy has led to various clinical oncology guidelines that outline 
maintenance therapy as an option for some patients.1–3
In the PARAMOUNT continuation maintenance trial, 
PFS and OS were significantly improved when patients with 
advanced nonsquamous NSCLC, who had not progressed 
after four cycles of pemetrexed–cisplatin induction, were 
treated with pemetrexed continuation maintenance therapy 
compared with placebo.8,9 Pemetrexed continuation mainte-
nance resulted in a statistically significant reduction in the risk 
of disease progression over placebo (hazard ratio [HR] = 0.62; 
95% confidence interval [CI], 0.49–0.79; p < 0.0001) and 
improved OS (HR = 0.78; 95% CI, 0.64–0.96; p = 0.0195), 
with median OS, measured from randomization, 13.9 months 
pemetrexed versus 11.0 months placebo.
Additional prespecified analyses of the OS and PFS 
PARAMOUNT data yielded evidence that the relative treat-
ment effect of pemetrexed was internally consistent across sub-
groups and similar to that observed in the primary PFS and OS 
analyses.8,9 Nevertheless, the ongoing need to identify those 
patients who will benefit most from maintenance therapy and 
those who will not benefit suggests a more detailed look of 
the PARAMOUNT data is needed. Some have proposed that 
switch maintenance may be preferred for patients who exhibit 
stable disease (SD) after induction, as with the erlotinib results 
in the Sequential Tarceva in Unresectable NSCLCC (SATURN) 
trial,10 and that continuation maintenance may be favored 
for patients who exhibit a partial response (PR) or complete 
response (CR) during induction.11 A more detailed examina-
tion of PARAMOUNT data with this proposed paradigm in 
mind is in order. Likewise, awareness that the SD designation 
is given to a fairly heterogeneous group, including patients 
whose response to induction therapy varies from minimal 
response to minimal progression, also supports a more detailed 
examination of the PARAMOUNT data set. Therefore, addi-
tional descriptive subgroup analyses of the PFS and OS data of 
the PARAMOUNT phase III clinical trial were undertaken to 
determine if the efficacy of pemetrexed continuation mainte-
nance therapy is more pronounced in certain subgroups.
METHODS
Study Design and Patients
Other articles have described study methodology in 
depth.8,12 To summarize, this phase III trial had two  treatment 
phases: an induction phase of four cycles of pemetrexed (intra-
venously [IV], 500 mg/m2) and cisplatin (IV, 75 mg/m2) admin-
istered on day 1 of a 21-day cycle and a maintenance phase in 
which eligible patients were randomized (2:1) to continuation 
pemetrexed (IV, 500 mg/m2) or placebo (IV, 0.9% sodium chlo-
ride), both on day 1 of 21-day cycles. Criteria for patients to be 
eligible for induction included advanced nonsquamous NSCLC 
(stage IIIB/IV) (Lung Cancer Staging Guidelines, Version 5),13  
at least one measureable lesion per Response Evaluation Criteria 
in Solid Tumors (RECIST 1.0),14 Eastern Cooperative Oncology 
Group performance status (PS) of 0/1,15 and no previous sys-
temic chemotherapy for lung cancer. Patient eligibility for 
maintenance included PR or CR or SD following four cycles of 
pemetrexed–cisplatin induction therapy and PS of 0/1.
Patients were randomized to a maintenance arm and began 
treatment within 7 days, 21 to 42 days from day 1 of induction 
cycle 4. Randomization to treatment was stratified by the follow-
ing prognostic factors: disease stage before induction (IIIB versus 
IV), tumor response to induction (CR–PR versus SD), and PS 
before randomization (0 versus 1). Maintenance treatment con-
tinued until disease progression, unacceptable toxicity, or patient–
physician decision. Patients were followed until death or study 
closure. During both phases of the study, patients were admin-
istered folic acid, vitamin B
12
 supplementation, and prophylactic 
dexamethasone as recommended on the pemetrexed label. Dose 
adjustments and cycle delays (≤42 days) were permitted to resolve 
toxicities. Tumor measurement proceeded as previously reported.8 
Toxicity was assessed before each cycle using the Common 
Terminology Criteria for Adverse Events, version 3.0.16
The protocol was approved at each site by an ethics 
review board. Principles of good clinical practice and the 
Declaration of Helsinki ethical principles were used to guide 
study conduct. Each patient provided written informed con-
sent before treatment initiation.
Statistical Analyses
All patients randomized to maintenance were included 
in the efficacy analyses (intent-to-treat). The unadjusted Cox 
proportional hazards regression model was used to estimate 
PFS and OS HRs and 95% CI.17 Kaplan–Meier analyses were 
used to estimate median PFS and OS.18 Waterfall plots were 
also used to illustrate treatment efficacy for individual patients. 
Differences in survival estimates between pemetrexed and 
placebo arms were assessed using a two-sided log-rank test. 
Using known prognostic variables, post hoc descriptive analy-
ses were undertaken to expand on OS analyses in the Statistical 
Analysis Plan. Statistical Analysis Software (version 9.1.3; 
SAS Institute, Cary, NC) was used for all statistical analyses.
RESULTS
As previously reported, 939 patients were enrolled in the 
induction phase of the study at 83 primarily European sites; 
700 of these patients (75%) achieved disease control (tumor 
response or SD) and 637 patients (68%) completed four 
cycles of pemetrexed–cisplatin.8 Subsequently, 539 patients 
who completed four cycles of induction and who exhibited 
both disease control and PS 0 to 1 were randomized 2:1 to 
maintenance treatment (359 pemetrexed, 180 placebo).
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To explore whether any patient or disease charac-
teristic was indicative of longer or shorter survival among 
patients receiving pemetrexed maintenance therapy, patients 
were divided into groups based on survival time (Table 1). 
Although the small patient numbers in some subgroups pre-
clude definitive conclusions, in general, the indicated base-
line patient and disease characteristics of patients surviving 
longer periods were comparable to those surviving shorter 
periods. This includes patient characteristics of age, sex, 
ethnic origin, prior smoking status, and tumor histology and 
stage. These data suggest that there is no baseline character-
istic that identifies those patients who receive a long-term 
survival benefit from pemetrexed maintenance therapy from 
those patients who stop maintenance treatment early due to 
disease progression.
Since adverse events (AEs) during induction therapy 
can impact physician decision whether to continue with main-
tenance therapy, we examined if induction AEs were indica-
tive of survival duration among patients receiving pemetrexed 
maintenance therapy (Table 2). No grade 3 and 4 induction 
toxicities were experienced disproportionately by patients 
with OS of shorter duration. Likewise, low grade toxicities 
(grade 1–2) were not experienced more frequently by patients 
with shorter survival times (data not shown).
Patient response to induction therapy has also been pro-
posed as an indicator of the utility of maintenance therapy. 
A prior report noted that both CR–PR and SD subgroups of 
the pemetrexed maintenance arm showed numerically positive 
survival results, although the study was not powered for these 
subgroups and the differences were not statistically signifi-
cant.8 Further analysis also showed that the response by treat-
ment interaction term was not significant as assessed using the 
Cox model of response, treatment, and response by treatment 
interaction (CR–PR versus SD; p = 0.731).8 A compilation of 
maintenance cycle data for the induction response subgroups 
revealed that on the pemetrexed arm, patients with an induc-
tion response of CR–PR received a similar mean number of 
cycles as those with an induction response of SD (8.5 ver-
sus 7.5; range, 0–44 and 0–37, respectively) but a greater 
median number of cycles (six versus four, respectively). On 
the placebo arm, both induction response groups received 
similar mean and median number of cycles (CR–PR: median, 
4.7 cycles; mean, four cycles; range, 0–38 cycles; SD: median, 
5.1 cycles; mean four cycles; range, 0–36 cycles). In addition, 
TABLE 1.  Comparison of Baseline Characteristics of Pemetrexed Arm Patients Surviving Longer vs. Shorter Periods
Baseline 
Characteristics
All Pemetrexed 
Arm Patients
Patients with Specific Baseline Characteristics within Subgroups Defined by Survival Intervalsa
0–3 Mob >3–6 Mo >6–12 Mo >12–18 Mo >18–24 Mo >24 Mo
No. of patients, n 359 26 61 72 62 59 79
Median age, yr 61 61 60 59 61 63 63
Age, % of patients
 <65 66 65 79 71 61 64 58
 ≥65 34 35 21 29 39 36 42
Sex, % of patients
 Male 56 58 61 58 68 44 49
 Female 44 42 39 42 32 56 51
Origin, % of patients
 White 94 85 97 93 94 97 96
 Asian 5 12 3 4 6 3 3
 African 1 4 0 3 0 0 1
Smoker, % of patients
 Ever smoker 76 89 90 81 76 63 68
 Never smoker 23 12 10 19 24 36 30
Stage, % of patients
 IIIB 9 8 10 11 6 5 10
 IV 91 92 90 89 94 95 90
Histology, % of patientsc
 Adenocarcinoma 86 81 75 92 90 86 89
 Large cell 7 8 12 1 7 9 6
 Other/NOS 7 12 13 7 3 5 5
aSubgroup listings not totaling 100% are due to rounding or missing data.
bAuthors also examined the 0- to 3-month data in a 6-week increments (0–1.5 mo, >1.5–3 mo). The number of patients in the 0- to 1.5-month increment was small (n = 6), so it was 
combined with the >1.5- to 3-month group (n = 20). The baseline characteristic data for patients surviving the first 1.5 mo did not reveal any trends.
cGrouped by World Health Organization classification of lung tumors. The subcategory “Other” represents patients with a primary diagnosis of NSCLC whose disease did not 
clearly qualify as adenocarcinoma or large-cell carcinoma and includes NSCLC not otherwise specified, poorly differentiated, and adenocarcinoma, mucinous. The adenocarcinoma 
category includes patients with the bronchoalveolar classification.
n, population size; NOS, not otherwise specified; NSCLC, non–small-cell lung cancer.
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patients on pemetrexed maintenance therapy were found to 
have a greater mean number of cycles than patients on placebo 
maintenance therapy.
To further analyze induction response as a potential 
indicator of survival outcome, patients on both arms were sep-
arated into induction response subgroups (CR–PR versus SD) 
then segregated further into groups based on length of sur-
vival (Table 3). Similar to the data displayed in Tables 1 and 2, 
among patients who received maintenance pemetrexed, the 
proportion of patients with an induction response of CR–PR 
versus SD was largely consistent over time. Patients who experi-
enced limited benefit from maintenance treatment (OS < 3 mo) 
are few in number, hindering analysis, but this population 
contains both patients with a tumor response and those with 
SD. In the two induction response groups (CR–PR and SD), 
similar proportions of patients lived greater than 18 months 
(as measured from randomization to maintenance therapy). 
Interestingly, OS also did not seem to be impacted by type 
TABLE 2.  Select AEs as Indicators of Length of Overall Survival among Patients Receiving Pemetrexed Continuation 
Maintenance Therapya
Grade 3/4 AE Types
Pemetrexed  
(n = 359) 
n (%)
Patients with Specific AEs during Induction in Subgroups Defined by Survival Intervals
0–3 Mo, 
n (%)b
>3–6 Mo, 
n (%)
>6–12 Mo, 
n (%)
>12–18 Mo, 
n (%)
>18–24 Mo, 
n (%)
>24 Mo, 
n (%)
Hematologic toxicities
 Any hematologic toxicity 52 (14.5) 7 (1.9) 7 (1.9) 11 (3.1) 11 (3.1) 4 (1.1) 12 (3.3)
 Anemia 13 (3.6) 4 (1.1) 1 (0.3) 1 (0.3) 2 (0.6) 1 (0.3) 4 (1.1)
 Neutropenia 35 (9.7) 3 (0.8) 6 (1.7) 9 (2.5) 8 (2.2) 2 (0.6) 7 (1.9)
 Leukopenia 4 (1.1) 0 1 (0.3) 0 1 (0.3) 0 2 (0.6)
 Thrombocytopenia 2 (0.6) 0 0 0 0 1 (0.3) 1 (0.3)
 Febrile neutropenia 5 (1.4) 0 0 1 (0.3) 3 (0.8) 0 1 (0.3)
Nonhematologic toxicities
 Nausea 13 (3.6) 1 (0.3) 1 (0.3) 1 (0.3) 4 (1.1) 3 (0.8) 3 (0.8)
 Fatigue 6 (1.7) 1 (0.3) 1 (0.3) 0 2 (0.6) 2 (0.6) 0
 Vomiting 16 (4.5) 3 (0.9) 2 (0.6) 1 (0.3) 2 (0.6) 6 (1.7) 2 (0.6)
 Mucositis–stomatitis 1 (0.3) 0 0 0 1 (0.3) 0 0
 Renal failure 2 (0.6) 1 (0.3) 1 (0.3) 0 0 0 0
aAEs listed are those stipulated by investigators as possibly related to drug administration.
bAuthors also examined the 0- to 3-month data in 6-week increments (0–1.5 mo, >1.5–3 mo). The number of patients in the 0- to 1.5-month increment was small (n = 6), so it was 
combined with the >1.5- to 3-month group (n = 20). The AE data for patients surviving the first 1.5 mo did not reveal any trends.
AEs, adverse events; n, population size.
TABLE 3.  Induction Response and PS as Indicators of Overall Survival among Patients Receiving Continuation Maintenance 
Pemetrexed or Placebo
All Patients
Patients with Specific Induction Outcomes in Subgroups Defined by Survival Intervalsa
0–1.5 Mo >1.5–3 Mo >3–6 Mo >6–12 Mo >12–18 Mo >18–24 Mo >24 Mo
Pemetrexed arm patients, n 359 6 20 61 72 62 59 79
 Response to induction therapy
  CR–PR, % of patients 44 33 55 43 43 37 49 47
  SD, % of patients 53 67 30 51 57 63 49 51
 PS
  PS 0, % of patients 32 17 15 26 33 26 34 42
  PS 1, % of patients 68 83 80 74 67 74 66 58
Placebo arm patients, n 180 4 7 38 53 29 26 23
 Response to induction therapy
  CR–PR, % of patients 42 50 71 40 38 31 46 52
  SD, % of patients 53 50 29 50 57 66 50 44
 PS
  PS 0, % of patients 33 50 29 21 36 38 31 44
  PS 1, % of patients 66 50 71 76 62 62 69 57
aSubgroup listings not totaling 100% are due to rounding or missing data.
CR, complete response; PR, partial response; SD, stable disease; PS, performance status.
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of induction response among patients who received placebo 
for maintenance therapy. In general, these results suggest that 
tumor response to induction as assessed by RECIST desig-
nations of tumor response and SD are not indicative of OS 
outcome for pemetrexed continuation maintenance treatment.
Because RECIST tumor efficacy designations collapse 
smaller positive tumor responses (<30% decrease in tumor size) 
and smaller negative response (<20% increase in tumor size) into 
one category (SD), and, likewise, group all tumor responses 
less than complete tumor disappearance into a PR grouping, 
it is of value to look at tumor size change in individual patient 
records to further examine its relationship with survival. For 
each randomized patient, the percent change in the sum of the 
longest diameter of target lesions diameters (i.e., a normal-
ized index of tumor growth or shrinkage) from baseline to the 
fourth induction cycle was graphed in a waterfall plot (left y 
axis), along with an indication of each patient’s PFS or OS time 
(right y axis) (Fig. 1A and B). The plot illustrates the expected 
variation within the SD designation (green bars), with a few 
patients showing a slight increase (up to 23%) in tumor size, 
with the majority of patients showing either no change in 
tumor size or modest decrease in tumor size (<30% decrease 
in the sum of target tumor lesion diameters). OS for patients 
with SD is variable, with the associated points ranging from 
approximately 0 to 37 months, as reported above. Likewise, 
patients with the designation of PR or CR also show a vari-
ability in the percent change of the sum of target lesion mea-
surements ranging from 30% to 100%. OS for this group of 
patients ranged from 0 to 44 months, a range similar to the 
patients with SD. In general, these results suggest that the 
degree of tumor shrinkage after induction is not an indicator of 
OS outcome. Analysis of the data in Figure 1B (through scat-
tergram, plotting individual patient induction response tumor 
data versus OS time [months]) confirmed this finding (data not 
shown). Computation of Spearman’s rank correlation coeffi-
cient revealed no correlation between the percentage of tumor 
reduction and final OS (Spearman’s rho = –0.019; p = 0.674).
Additional analyses focused on the impact of PS on 
efficacy outcomes among patients with advanced NSCLC 
receiving maintenance therapy. When patients on both arms 
were divided into subgroups based on PS (0 versus 1) and 
OS, a greater proportion of pemetrexed arm patients with PS 
FIGURE 1.  Waterfall plot of induc-
tion response of patients treated 
with pemetrexed. The waterfall plots 
display individual patient induction 
response data expressed as percent 
change in the sum of the longest 
diameter of target lesions as mea-
sured at baseline and visit 4 of the 
induction period. Best induction 
tumor response for each patient 
(SD, PR, or CR) is indicated by the 
color of the data bar. A, PFS time 
(months) (right y axis) for each 
patient as indicated by points. B, OS 
time (months) (right y axis) for each 
patient, also indicated by points. SD, 
stable disease; PR, partial response; 
CR, complete response; PFS, progres-
sion-free survival; OS, overall survival; 
BSC, best supportive care.
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1 had shorter survival times than those with PS 0 (Table 3). 
Although the study was not powered for subgroup analyses, 
data were analyzed by Kaplan–Meier estimation for descrip-
tive purposes (Fig. 2A and B). Among patients on the peme-
trexed arm, PS 0 patients were found to survive longer than 
PS 1 patients: median OS PS 0 patients: 17.2 months (95% 
CI, 14.2–22.7) versus PS 1 patients: 12.9 months (95% CI, 
11.8–15.3) (log rank p = 0.023). When median OS was com-
pared between PS 0 and PS 1 patients who received placebo 
for maintenance therapy, there was no statistical differ-
ence (p = 0.423) (Table 4). Nevertheless, both PS 0 and PS 
1 patients receiving pemetrexed maintenance therapy sur-
vived longer than patients with similar PS receiving placebo 
(pemetrexed PS 0: 17.2 months versus placebo PS 0: 12.9, 
p = 0.059; pemetrexed PS 1: 12.9 months versus placebo PS 
1: 10.7, p = 0.121). These results were directional, but not sig-
nificant, likely influenced by inadequate sample size as the 
study was not powered for this analysis.
A further parameter that might influence the efficacy of 
pemetrexed continuation maintenance therapy is the length of 
the interval between completion of induction therapy and the 
start of maintenance therapy. By protocol specification, main-
tenance therapy was to start within 21 to 42 days after the start 
of cycle 4. Median time from start of induction therapy to the 
FIGURE 2.  Kaplan–Meier plots of 
overall survival in performance status 
subgroups. The Kaplan–Meier plots 
depict overall survival by perfor-
mance status 0 (A) and overall sur-
vival by performance status 1 (B).
TABLE 4.  OS of Maintenance Therapy Subgroups
Median OS  
(95% CI) (Mo)
No. of 
Patients
Event 
Number
Log-rank 
 p
ECOG PS
 Pemetrexed arm patients
  0 17.2 (14.2–22.7) 113 74
0.023
  1 12.9 (11.8–15.3) 245 181
 Placebo arm patients
  0 12.9 (9.8–15.8) 60 46
0.423
  1 10.7 (8.7–12.3) 118 93
Time from end of induction therapy to start of maintenance therapya
 Pemetrexed arm patients
  <7 days 17.0 (15.6–19.1) 230 159
0.7685
  ≥7 (but ≤30) days 16.3 (15.1–20.9) 127 95
 Placebo arm patients
  <7 days 14.2 (12.9–17.9) 133 104
0.3934  ≥7 (but ≤30) days 12.9 (10.6–15.5) 45 36
aAssumes a 21-day cycle 4.
OS, overall survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology 
Group; PS, performance status.
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start of maintenance treatment was 3 months on both arms. 
Time from end of induction to the start of maintenance assum-
ing a 21-day cycle 4: median 3 days, range –2 to 30 days, with 
the majority of patients (68%) initiated maintenance therapy 
immediately (<7 days) after the completion of induction. The 
difference in survival in patients who started maintenance 
therapy less than 7 days from the completion of induction 
treatment and patients starting greater than or equal to 7 days 
after the completion of induction treatment was determined. 
As shown in Table 4, median OS is not significantly different 
among patients who begin maintenance therapy in less than 
7 days versus greater than or equal to 7 days (but ≤30 days).
DISCUSSION
Phase III clinical trials have identified switch and con-
tinuation maintenance chemotherapy strategies that result in 
improved PFS and OS, while maintaining quality of life in 
advanced NSCLC patients.7–9,19 Examination of the Kaplan–
Meier PFS and OS plots in the PARAMOUNT trial reveals 
that approximately 25% of patients progressed or died at the 
first 6-week evaluation of pemetrexed continuation mainte-
nance therapy, whereas 32% of PARAMOUNT patients had 
survived 2 years after randomization.8,9 Similarly, other main-
tenance trials have patients who survive substantially greater 
or lesser periods than others in the treatment arm. Interest has 
grown in predicting which patients may benefit most from 
maintenance therapy to balance any increased toxicities with 
quality-of-life concerns and for economic considerations. 
Previous studies have identified a number of factors that may 
have bearing on the success of maintenance therapy outcome. 
These have been summarized in the recent review article by 
Gerber and Schiller4 and include tumor histology, response to 
first-line therapy, PS, likelihood of receiving therapy at pro-
gression, and molecular characteristics, in particular for those 
agents with tumor targets with variable expression (e.g., acti-
vating EGFR and KRAS mutations).
Tumor histology (nonsquamous subgroups) and other 
baseline and disease characteristics including patient age, 
sex, ethnic origin, smoking status, and disease stage were pre-
viously examined by Forest Plot for their effect on the PFS 
and OS efficacy parameters.8,9 In each subgroup, the impact 
of pemetrexed continuation maintenance treatment on OS and 
PFS was consistently positive. Likewise, in this analysis sum-
mary, neither those patients with limited survival (OS <3 mo) 
nor those patients with extensive survival (OS >24 mo) were 
observed to cluster in any particular baseline patient or disease 
characteristic group. The median age and the proportion of 
patients greater than 65 years were nearly constant. Likewise, 
subgroups within smoking status, disease stage, ethnic origin, 
and sex categories had a relatively consistent percentage of 
patients in the various survival time categories. The survival 
interval of 0 to 3 months had too few patients to draw con-
clusions, but one could note that these patients who benefit-
ted minimally from treatment were represented in all of the 
subgroups. Type and severity of AEs experienced by patients 
during induction were also examined to determine if they 
impacted length of survival; no clear association was observed.
Another parameter widely considered potentially impact-
ful on maintenance results is the response to induction therapy. 
The initial pemetrexed switch maintenance trial7 and the cur-
rent PARAMOUNT trial8,9 reported that tumor response during 
induction did not have bearing on survival parameters. In con-
trast, the SATURN trial found that erlotinib as a switch main-
tenance agent only yielded an OS benefit for patients with SD 
after induction (HR = 0.72 SD versus HR = 0.90 for patients 
with a tumor response),10 an outcome reflected in the mainte-
nance indication for which erlotinib is approved for treatment 
in Europe. In a separate study by Fidias et al.,20 docetaxel was 
found to be effective as a switch maintenance agent only for 
the cohort of patients with a tumor response after induction 
(HR = 0.61 versus 1.02 for patients with SD).4 Results from 
the study by Pérol et al.11 led to the suggestion that induction 
response may affect survival results when using continuation 
maintenance. The post hoc analyses reported herein sought to 
further explore the initial PARAMOUNT finding. When patients 
were divided into induction response groups (CR–PR versus 
SD) and the percentage of pemetrexed arm patients was com-
pared with OS time falling within specific intervals, the propor-
tion of patients in the induction response groups was relatively 
consistent. When this descriptive analysis was expanded to look 
at individual patient data through a waterfall plot, both the PFS 
and OS outcomes were entirely random relative to the induction 
tumor response. This was true for patients who manifested SD 
as slight tumor growth and those who exhibited modest target 
tumor shrinkage. Likewise, patients who had been character-
ized as partial responders with target tumor shrinkage in the 
range of greater than 30% to 93% exhibited a wide variation in 
PFS and OS. Further analysis with a scattergram confirmed the 
lack of correlation, thus leading to the conclusion that degree 
of tumor reduction does not predict outcome of continuation 
maintenance in the PARAMOUNT study.
This finding differs from that of SATURN10 and other 
studies that indicate patients with SD following first-line che-
motherapy have a poorer prognosis than patients with a tumor 
response. Comparing the SATURN study with PARAMOUNT, 
one notes that the induction regimen for SATURN consisted of 
four cycles of a mix of platinum-based doublet chemotherapy, 
whereas in PARAMOUNT, all patients received pemetrexed–
cisplatin for induction. Whether this difference has bearing 
on the similar responsiveness of the induction response sub-
groups (SD and PR–CR) remains to be investigated.
The waterfall plots used to confirm the dissociation of 
induction tumor response and survival outcomes were also 
a useful tool to visualize the substantial variability in tumor 
response within a group of patients. Expressing tumor response 
data in terms of RECIST categories may be helpful for analyti-
cal purposes, but it yields an incomplete picture of the results. 
In particular, the SD category represents a highly heteroge-
neous population as evidenced by the waterfall plots and corre-
sponding survival data. Indeed, these plots underscore the need 
to review how well a patient responds to treatment through 
tolerability, symptomatic, and radiological assessment, when 
determining whether to recommend maintenance treatment.
PS is a known prognostic factor for patient survival 
in advanced NSCLC.21 Descriptive analyses identified a 
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significant improved survival outcome for pemetrexed con-
tinuation maintenance patients with PS 0 over those with 
PS 1. Interestingly, PS impacted results sufficiently that the 
PS 1 pemetrexed cohort had a median OS value comparable 
to the placebo PS 0 cohort. Nonetheless, both PS 0 and PS 
1 pemetrexed arm subgroups had greater median OS than 
patient subgroups with the same PS who received placebo 
maintenance therapy. These results are comparable to recently 
published PS and symptom burden analyses of the phase III 
switch maintenance pemetrexed trial.22 Although both phase 
III trial analyses were retrospective and derived from studies 
not suitably powered for subgroup analysis, they both support 
the prognostic value of PS and underscore its importance as 
an indicator of suitability for maintenance. Furthermore, they 
substantiate the notion of not delaying maintenance treatment 
in favor of second-line treatment as the delay might entail 
PS decline. Interestingly, a recent retrospective analysis con-
cluded that patients with poorer PS (≥2) should be considered 
candidates for well-tolerated maintenance therapy because as 
a cohort, they are less likely to receive second-line therapy.23 
Nevertheless, a study by Brodowicz et al.24 observed that 
patients with poorer PS (Karnofsky PS ≤ 80) did not exhibit a 
survival benefit with continuation maintenance gemcitabine, 
and a second trial that included 60% PS 2 patients also failed 
to demonstrate improved survival with continuation mainte-
nance gemcitabine.25 Hence, further studies will be necessary 
to determine if patients with PS ≥2 receive any benefit from 
continuation maintenance pemetrexed.
Further examination of the concept of delayed treatment 
led to the analysis whether longer or shorter intervals between 
the conclusion of induction and the initiation of maintenance 
treatment might have bearing on survival results. An analysis 
of survival among patients receiving pemetrexed who initiated 
maintenance within a week (<7 days) after the end of induction 
versus those who initiated maintenance after a longer period, 
but one still within protocol specifications (>7 and ≤30 days), 
showed that the brief delay in maintenance initiation had no 
measurable effect on survival results. Nevertheless, prospec-
tive studies are needed to fully examine the ongoing consider-
ation of maintenance treatment versus second-line treatment.26 
Such studies should include prespecified, fully powered sub-
group analyses to examine the impact of potentially predictive 
factors and assess factors identified with a lower likelihood of 
receipt of second-line chemotherapy as possible predictors of 
patients who will benefit from maintenance therapy.4
In addition to the aforementioned limitations inherent in 
retrospective analyses of study data not powered for subgroup 
analysis, the PARAMOUNT study and associated analyses are 
limited by the lack of data on the molecular characteristics of 
patient tumors associated with longer or shorter survival out-
comes. Arguably, although analysis of such tissue at this time 
would be an open-ended inquiry, molecular genomic studies 
are thought of as pivotal future determinants of individualized 
patient care; therefore, appropriate tissue samples should be 
acquired when possible.
In summary, the analyses summarized here show that 
other than the PS prognostic marker, no baseline or clinical 
parameter identifies a subgroup of patients more or less likely 
to benefit from pemetrexed maintenance therapy. Survival 
was consistent across subgroups, including tumor response 
to induction. Degree of tumor shrinkage was not correlated 
with survival; both long-term and short-term survivors were 
variable in tumor response, with some long-term survivors 
characterized as having SD. These data underscore the useful-
ness of pemetrexed continuation maintenance therapy follow-
ing four cycles of cisplatin-containing induction therapy for 
nonprogressing patients with PS 0 to 1. Furthermore, these 
analyses emphasize the importance of making maintenance 
treatment decisions based on a full clinical assessment of each 
patient and with an awareness of each patient’s preferences 
and needs.
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